Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-12-13FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental application for Tecfidera (dimethyl fumarate).
-
FDA approval · 2023-12-13FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
FDA approval · 2023-12-13FDA Approved: BAFIERTAM — Supplemental Application (Banner Life Sciences LLC)
The FDA approved a supplemental application for BAFIERTAM (monomethyl fumarate) from Banner Life Sciences LLC.
-
FDA approval · 2023-12-06FDA Approved: MAVENCLAD — Supplemental Application (EMD Serono, Inc.)
The FDA has approved a supplemental application for MAVENCLAD (cladribine) submitted by EMD Serono, Inc.
-
EMA approval · 2023-11-23EMA Authorised: Betaferon (interferon beta-1b) — Bayer AG
EMA authorised Betaferon (interferon beta-1b) by Bayer AG for multiple sclerosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-11-16FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) from Novartis Pharmaceuticals Corporation. The action involves a ch…
-
FDA approval · 2023-11-16FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA has approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc.
-
FDA approval · 2023-10-12FDA Approved: BACLOFEN — Supplemental Application (Palmetto Pharmaceuticals Inc.)
FDA approved a supplemental application for baclofen from Palmetto Pharmaceuticals Inc., indicating an update to the drug's existing approva…
-
FDA approval · 2023-09-12FDA Approved: BACLOFEN — Supplemental Application (TruPharma LLC)
FDA approved TruPharma LLC's supplemental application for baclofen, enabling a new generic version to be marketed.
-
FDA approval · 2023-08-24FDA Approved: TYRUKO — Original Application (Sandoz Inc)
FDA approved TYRUKO (natalizumab-sztn) from Sandoz Inc under an original Biologics License Application as a natalizumab biosimilar. The appr…
-
FDA approval · 2023-08-18FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. The action expands the drug's approved indication…
-
FDA approval · 2023-08-10FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for Mayzent (siponimod) submitted by Novartis Pharmaceuticals Corporation to update the product labe…
-
FDA approval · 2023-08-10FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCL) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-07-28FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Betaseron (interferon beta-1b) submitted by Bayer HealthCare Pharmaceuticals Inc. This action up…
-
FDA approval · 2023-07-28FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for AVONEX (interferon beta-1a) from Biogen. The action updates the labeling or approved indicat…
-
FDA approval · 2023-07-28FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Plegridy Pen, a device for administering peginterferon beta-1a by Biogen.
-
FDA approval · 2023-07-28FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for Rebif (interferon beta-1a) submitted by EMD Serono, Inc.
-
FDA approval · 2023-07-05FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved Sandoz's supplemental application for GLATOPA, a generic glatiramer acetate product, for use in treating multiple sclerosis.
-
FDA approval · 2023-06-08FDA Approved: BACLOFEN — Original Application (Slayback Pharma LLC)
The FDA approved Slayback Pharma LLC's original application for a generic baclofen product for the treatment of spasticity associated with m…
-
FDA approval · 2023-05-15FDA Approved: TERIFLUNOMIDE — Original Application (Natco Pharma USA LLC)
FDA approved Natco Pharma USA LLC's original application for generic teriflunomide, a disease-modifying therapy for relapsing forms of multi…
-
FDA approval · 2023-05-08FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA (glatiramer acetate) from Sandoz Inc, providing a generic version of glatiramer acet…
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for dalfampridine from Aurobindo Pharma Limited, enabling a generic version of the drug. This action…
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for dalfampridine, approving the generic dalfampridine product.
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for a generic dalfampridine product from Ascend Laboratories, LLC.
-
FDA approval · 2023-04-19FDA Approved: DALFAMPRIDINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for dalfampridine submitted by Actavis Pharma, Inc., resulting in an updated regulatory action for t…